Leo Pharma

Type: Company
Name: Leo Pharma
Web Address: http://www.leo.se
First reported 20 hours ago - Updated 5 hours ago - 1 reports

Antares Pharma to Host Third Quarter 2014 Operating and Financial Results Conference Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release itsthird quarter 2014 financial results before the market opens onThursday, November 6, 2014 and host a conference call at 8:30 a.m. ET(Eastern Time) to discuss the results. Eamonn P. ... [Published BioPortfolio - 20 hours ago]
First reported Oct 29 2014 - Updated Oct 29 2014 - 1 reports

Leo Pharma reports positive results in its trial of Daivobet in psoriasis

Independent Danish dermatology specialist Leo Pharma has demonstrated significant improvement in psoriasis disease severity in trials of its Daivobet gel (calcipotriol and betamethasone).The study analysed 1,795 patients in Europe who had not responded ... [Published Pharma Letter - Oct 29 2014]
First reported Oct 28 2014 - Updated Oct 29 2014 - 1 reports

28-10-2014 International study shows improved outcomes for psoriasis patients

Data published in JEADV demonstrate significant improvement in disease severity and patient preference following treatment with calcipotriol/betamethasone dipropionate (Daivobet® gel)28 October 2014, Ballerup, Denmark - Interim results from one of the ... [Published Noodls - Oct 28 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

ω-3FA supplements potentially useful for lipid level management during isotretinoin therapy

Among patients undergoing isotretinoin treatment for acne, researchers have found ω-3 fatty acid supplements may be a useful addition for the management of lipid levels.The researchers obtained data for 39 patients with acne who were treated with isotretinoin ... [Published Orthopedics Today - Oct 21 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Keratinocyte cancer imposes heavy burden on Dutch population

Researchers found keratinocyte cancer has become a large burden in Dutch society, and because incidence rates continue to rise, management has become even more challenging.Data for all patients with newly diagnosed keratinocyte cancer were obtained from ... [Published Orthopedics Today - Oct 20 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

High Court finds psoriasis treatment patent invalid

The High Court has found that a patent for an ointment used to treat psoriasis was invalid for obviousness. ( Teva UK Ltd and another v Leo Pharma AS and another [2014] EWHC 3096 (Pat), 6 October 2 ... [Published Practical Law Company - Oct 09 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

LEO Pharma Inc. Announced New Taclonex® calcipotriene and betamethasone dipropionate Topical Suspension, 0.005%/0.064% Indication for Treatment of...

LEO Pharma Inc. Announced New Taclonex calcipotriene and betamethasone dipropionate Topical Suspension, 0.005%/0.064% Indication for Treatment of Scalp Plaque Psoriasis in Pediatric Patients Ages 12-17By a News Reporter-Staff News Editor at Health & Medicine ... [Published Pharmacy Choice - Oct 09 2014]
First reported Oct 02 2014 - Updated Oct 03 2014 - 1 reports

Dermira IPO: Less Appealing In A Hot IPO Week

Summary DERM anticipates raising ~ $80 million on 5.4 million shares priced between $16 and $18 in its IPO on Friday. DERM’s IPO bookrunners are Citibank and Leerink Partners—solid but less illustrious than some peers. While Dermira has been successful ... [Published Seeking Alpha - Oct 02 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 2 reports

LEO Pharma Inc. Announced New Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% Indication for Treatment of Scalp Plaque Psoriasis in Pediatric Patients Ages 12-17

PARSIPPANY, N.J.--(EON: Enhanced Online News)--LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, today announced a new Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension indication for a topical combination treatment ... [Published EON Consumer - Sep 30 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Peril, Not Progress on Transatlantic Trade Deal

Only a year ago, hopes were high of rapid progress towards a transatlantic trade deal that would boost the European and USeconomies—and ease conditions for drug firms on both sides of the ocean. TTIP, the Transatlantic Trade and Investment Partnershi ... [Published Pharmaceutical Executive - Sep 08 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 2 reports

TACLONEX (Calcipotriene And Betamethasone Dipropionate) Ointment [LEO Pharma Inc.]

First reported Jul 15 2014 - Updated Jul 16 2014 - 1 reports

LEO Pharma & KLOX Technologies strike global dermatology deal

Dermatology leader LEO Pharma expands into acne, further pushing the boundaries of dermatology careKLOX gains access to global market, cementing its position as a leading Canadian life sciences specialty companyBALLERUP, Denmark and LAVAL, QC, July 15, ... [Published PR Newswire: Financial Services - Jul 15 2014]

Quotes

"One of the greatest unmet needs in psoriasis is adherence to topical treatment. Our aim with PSO-TOP is to demonstrate that adherence and clinical effectiveness of psoriasis treatment in a real-life setting can be improved as a result of optimised patient education and support, partnered with a treatment that has been shown to be preferred by patients. The full impact the TTOP in combination with calcipotriol/betamethasone dipropionate gel has on adherence will become evident when the full 64-week data are published. PSO-TOP has the potential to drive significant change in the way that doctors support their psoriasis patients through a truly holistic approach." *of patients who were not well controlled on previous therapy (topical or systemic)
Dr. Jerry Bagel, M D , Psoriasis Treatment Center of Central New Jersey, adds: "The psychological burden resulting in loss of self esteem from scalp psoriasis is especially devastating in the adolescent. The new indication for Taclonex in the treatment of scalp psoriasis in patients over the age of 12 offers the adolescent not only an effective therapy to combat the appearance of psoriasis, but can help them regain their self-esteem and self confidence which may transcend a lifetime."
...tricky in patients with marked renal insufficiency, and they may be contraindicated in patients with very low glomerular filtration rates as well, "so there is still a role for unfractionated heparin plus warfarin in these patients. It's not dead yet."
backup was evident in presentations from the Alliance for Healthcare Competitiveness, which "advocates for improved access"

More Content

All (23) | News (15) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Antares Pharma to Host Third Quarter 2014 Opera... [Published BioPortfolio - 20 hours ago]
Leo Pharma reports positive results in its tria... [Published Pharma Letter - Oct 29 2014]
28-10-2014 International study shows improved o... [Published Noodls - Oct 28 2014]
ω-3FA supplements potentially useful for lipid ... [Published Orthopedics Today - Oct 21 2014]
Keratinocyte cancer imposes heavy burden on Dut... [Published Orthopedics Today - Oct 20 2014]
High Court finds psoriasis treatment patent inv... [Published Practical Law Company - Oct 09 2014]
LEO Pharma Inc. Announced New Taclonex® calcip... [Published Pharmacy Choice - Oct 09 2014]
Dermira IPO: Less Appealing In A Hot IPO Week [Published Seeking Alpha - Oct 02 2014]
LEO Pharma Inc. Announced New Taclonex® (calcip... [Published EON Consumer - Sep 30 2014]
LEO Pharma Inc. Announced New Taclonex® (calcip... [Published Business Wire Health News - Sep 30 2014]
VTE Treatments Similarly Safe, Effective, but N... [Published American Journal of Public Health - Sep 24 2014]
Peril, Not Progress on Transatlantic Trade Deal [Published Pharmaceutical Executive - Sep 08 2014]
TTIP: From Hot Tip to Oblivion? [Published Pharmaceutical Executive - Aug 18 2014]
TACLONEX (Calcipotriene And Betamethasone Dipro... [Published DailyMed Drug Label Updates for the last seven ... - Aug 12 2014]
TACLONEX (Calcipotriene And Betamethasone Dipro... [Published DailyMed Drug Label Updates for the last seven ... - Aug 12 2014]
LEO Pharma & KLOX Technologies strike global de... [Published PR Newswire: Financial Services - Jul 15 2014]
LEO Pharma & KLOX Technologies strike global de... [Published Financial Services - Jul 15 2014]
Dovobet ointment approved to treat psoriasis vu... [Published PBR - News - Jul 07 2014]
Antares Pharma Reports First Quarter 2014 Opera... [Published Business Wire Health News - May 09 2014]
Stop Paying Lip Service to Patient-Centricity [Published Pharmaceutical Executive - Apr 10 2014]
Perrigo launches generic Taclonex ointment to t... [Published PharmaBiz - Apr 03 2014]
MobMe Gets A Shot in The Arm With Rs.16 Cr Ange... [Published Silicon India - Mar 03 2014]
Actinic Solar Keratosis Global Clinical Trials ... [Published BioPortfolio - Feb 20 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
LEO Pharma Inc. Announced New Taclonex® (calcip... [Published EON Consumer - Sep 30 2014]
PARSIPPANY, N.J.--(EON: Enhanced Online News)--LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, today announced a new Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension indication for a topical combination treatment ...
LEO Pharma Inc. Announced New Taclonex® (calcip... [Published Business Wire Health News - Sep 30 2014]
PARSIPPANY, N.J.--(BUSINESS WIRE)--LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, today announced a new Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension indication for a topical combination treatment of plaque ...
TACLONEX (Calcipotriene And Betamethasone Dipro... [Published DailyMed Drug Label Updates for the last seven ... - Aug 12 2014]
Updated Date: Aug 11, 2014 EST ...
TACLONEX (Calcipotriene And Betamethasone Dipro... [Published DailyMed Drug Label Updates for the last seven ... - Aug 12 2014]
Updated Date: Aug 11, 2014 EST ...
LEO Pharma & KLOX Technologies strike global de... [Published PR Newswire: Financial Services - Jul 15 2014]
Dermatology leader LEO Pharma expands into acne, further pushing the boundaries of dermatology careKLOX gains access to global market, cementing its position as a leading Canadian life sciences specialty companyBALLERUP, Denmark and LAVAL, QC, July 15, ...
1 2

Press Releases

sort by: Date | Relevance
LEO Pharma & KLOX Technologies strike global de... [Published Financial Services - Jul 15 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.